- Home
- CDNA vs ARVN Comparison
CDNA vs ARVN Comparison
Compare CDNA & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDNA
- ARVN
- Stock Information
- Founded
- CDNA 1998
- ARVN 2015
- Country
- CDNA United States
- ARVN United States
- Employees
- CDNA N/A
- ARVN N/A
- Industry
- CDNA Medical Specialities
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- CDNA Health Care
- ARVN Health Care
- Exchange
- CDNA Nasdaq
- ARVN Nasdaq
- Market Cap
- CDNA 1.1B
- ARVN 1.2B
- IPO Year
- CDNA 2014
- ARVN 2018
- Fundamental
- Price
- CDNA $18.92
- ARVN $9.03
- Analyst Decision
- CDNA Buy
- ARVN Strong Buy
- Analyst Count
- CDNA 8
- ARVN 13
- Target Price
- CDNA $29.43
- ARVN $40.92
- AVG Volume (30 Days)
- CDNA 912.4K
- ARVN 2.5M
- Earning Date
- CDNA 05-08-2025
- ARVN 05-06-2025
- Dividend Yield
- CDNA N/A
- ARVN N/A
- EPS Growth
- CDNA N/A
- ARVN N/A
- EPS
- CDNA 0.93
- ARVN N/A
- Revenue
- CDNA $333,785,000.00
- ARVN $263,399,999.00
- Revenue This Year
- CDNA $13.32
- ARVN N/A
- Revenue Next Year
- CDNA $14.99
- ARVN $7.99
- P/E Ratio
- CDNA $20.44
- ARVN N/A
- Revenue Growth
- CDNA 19.07
- ARVN 235.54
- 52 Week Low
- CDNA $7.42
- ARVN $7.91
- 52 Week High
- CDNA $34.84
- ARVN $46.51
- Technical
- Relative Strength Index (RSI)
- CDNA 36.93
- ARVN 24.95
- Support Level
- CDNA $17.73
- ARVN $7.91
- Resistance Level
- CDNA $22.61
- ARVN $18.93
- Average True Range (ATR)
- CDNA 1.31
- ARVN 1.51
- MACD
- CDNA -0.35
- ARVN -0.80
- Stochastic Oscillator
- CDNA 18.97
- ARVN 10.05
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.